XKRX:041960 (Korea (the Republic of))
Â
Ordinary Shares
â‚©
4010.00
(-3.61%)
Nov 29
Business Description
Komipharm International Co Ltd
ISIN : KR7041960006
Share Class Description:
XKRX:041960: Ordinary SharesCompare
Compare
Traded in other countries / regions
041960.Korea IPO Date
2001-10-30Description
Komipharm International Co Ltd is involved in the healthcare sector based in Korea. Its core business includes development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The company produces its products under two divisions: veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle. The other division is made up of veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis and swine erysipelas.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.63 | |||||
| Equity-to-Asset | 0.49 | |||||
| Debt-to-Equity | 0.67 | |||||
| Debt-to-EBITDA | 2.32 | |||||
| Interest Coverage | 1.15 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 3.54 | |||||
| Beneish M-Score | -1.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 4.9 | |||||
| 3-Year EBITDA Growth Rate | -36.3 | |||||
| 3-Year EPS without NRI Growth Rate | -23.5 | |||||
| 3-Year FCF Growth Rate | -33.5 | |||||
| 3-Year Book Growth Rate | -9.5 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.11 | |||||
| 9-Day RSI | 44.41 | |||||
| 14-Day RSI | 44 | |||||
| 6-1 Month Momentum % | 5.42 | |||||
| 12-1 Month Momentum % | -14.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.31 | |||||
| Quick Ratio | 0.99 | |||||
| Cash Ratio | 0.52 | |||||
| Days Inventory | 159.99 | |||||
| Days Sales Outstanding | 93.98 | |||||
| Days Payable | 47.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.1 | |||||
| Shareholder Yield % | 1.08 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 35.64 | |||||
| Operating Margin % | 5.56 | |||||
| Net Margin % | 20.8 | |||||
| FCF Margin % | 0.25 | |||||
| ROE % | 19.12 | |||||
| ROA % | 9.2 | |||||
| ROIC % | 2.83 | |||||
| ROC (Joel Greenblatt) % | 19.25 | |||||
| ROCE % | 21.55 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 24.25 | |||||
| PE Ratio without NRI | 92.43 | |||||
| Price-to-Owner-Earnings | 28.24 | |||||
| PS Ratio | 5.3 | |||||
| PB Ratio | 4.27 | |||||
| Price-to-Tangible-Book | 4.49 | |||||
| Price-to-Free-Cash-Flow | 518.77 | |||||
| Price-to-Operating-Cash-Flow | 76.74 | |||||
| EV-to-EBIT | 18.55 | |||||
| EV-to-EBITDA | 15.57 | |||||
| EV-to-Revenue | 5.39 | |||||
| EV-to-FCF | 2162.65 | |||||
| Price-to-Projected-FCF | 11.84 | |||||
| Price-to-Median-PS-Value | 0.2 | |||||
| Price-to-Graham-Number | 4.29 | |||||
| Price-to-Net-Current-Asset-Value | 106.34 | |||||
| Earnings Yield (Greenblatt) % | 5.37 | |||||
| FCF Yield % | 0.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Komipharm International Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 54,530.639 | ||
| EPS (TTM) (â‚©) | 166 | ||
| Beta | 0.21 | ||
| Volatility % | 17.4 | ||
| 14-Day RSI | 44 | ||
| 14-Day ATR (â‚©) | 132.085702 | ||
| 20-Day SMA (â‚©) | 4103.5 | ||
| 12-1 Month Momentum % | -14.72 | ||
| 52-Week Range (â‚©) | 3610 - 4940 | ||
| Shares Outstanding (Mil) | 69.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Komipharm International Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Komipharm International Co Ltd Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
Komipharm International Co Ltd Frequently Asked Questions
What is Komipharm International Co Ltd(XKRX:041960)'s stock price today?
The current price of XKRX:041960 is â‚©4010.00. The 52 week high of XKRX:041960 is â‚©4940.00 and 52 week low is â‚©3610.00.
When is next earnings date of Komipharm International Co Ltd(XKRX:041960)?
The next earnings date of Komipharm International Co Ltd(XKRX:041960) is .
Does Komipharm International Co Ltd(XKRX:041960) pay dividends? If so, how much?
Komipharm International Co Ltd(XKRX:041960) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers